PL2238982T3 - Środek do terapii mięsaka tkanek miękkich - Google Patents

Środek do terapii mięsaka tkanek miękkich

Info

Publication number
PL2238982T3
PL2238982T3 PL10162953T PL10162953T PL2238982T3 PL 2238982 T3 PL2238982 T3 PL 2238982T3 PL 10162953 T PL10162953 T PL 10162953T PL 10162953 T PL10162953 T PL 10162953T PL 2238982 T3 PL2238982 T3 PL 2238982T3
Authority
PL
Poland
Prior art keywords
compound
formula
therapeutic agent
soft tissue
tissue sarcoma
Prior art date
Application number
PL10162953T
Other languages
English (en)
Inventor
Tatsuo Ito
Toshifumi Ozaki
Mamoru Ouchida
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PL2238982T3 publication Critical patent/PL2238982T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL10162953T 2003-06-27 2004-06-25 Środek do terapii mięsaka tkanek miękkich PL2238982T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003183643 2003-06-27
EP10162953A EP2238982B8 (en) 2003-06-27 2004-06-25 Therapeutic agent for soft tissue sarcoma
EP04746840A EP1638541B1 (en) 2003-06-27 2004-06-25 Therapeutic agent for soft tissue sarcoma

Publications (1)

Publication Number Publication Date
PL2238982T3 true PL2238982T3 (pl) 2013-03-29

Family

ID=33549590

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10162953T PL2238982T3 (pl) 2003-06-27 2004-06-25 Środek do terapii mięsaka tkanek miękkich

Country Status (14)

Country Link
US (2) US7056883B2 (pl)
EP (2) EP1638541B1 (pl)
JP (1) JP4661782B2 (pl)
AT (1) ATE468113T1 (pl)
CA (1) CA2529840A1 (pl)
CY (1) CY1113534T1 (pl)
DE (1) DE602004027244D1 (pl)
DK (1) DK2238982T3 (pl)
ES (2) ES2397079T3 (pl)
MX (1) MXPA06000013A (pl)
PL (1) PL2238982T3 (pl)
PT (1) PT2238982E (pl)
SI (1) SI2238982T1 (pl)
WO (1) WO2005000332A2 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4238728B2 (ja) * 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
AU2003219555A1 (en) * 2002-04-05 2003-10-20 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
CN1777675A (zh) * 2003-02-19 2006-05-24 安斯泰来制药有限公司 预测组蛋白去乙酰化酶抑制剂抗肿瘤效果的方法
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20060040575A1 (en) * 2004-08-18 2006-02-23 Kelleher Karen A Reflective printing on flame resistant fabrics
EP1715334A1 (fr) * 2005-04-22 2006-10-25 Adamant Technologies SA Procédé utilisant un capteur électrochimique et électrodes formant ce capteur
NZ548087A (en) 2005-04-29 2010-10-29 Tomizo Yamamoto Rubber or resin foam containing zirconium or germanium
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
EP1920779A4 (en) * 2005-08-12 2010-03-10 Astellas Pharma Inc YW753 PREPARATION STABILIZATION TECHNIQUE
EP1924245A2 (en) * 2005-08-19 2008-05-28 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
GB0518720D0 (en) * 2005-09-14 2005-10-19 Hamlet Pharma Ab Therapeutic combination
AU2006311820A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Methods of using SAHA and erlotinib for treating cancer
CA2626679C (en) * 2005-11-04 2011-08-16 Merck & Co., Inc. Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
AU2006311808A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Methods of using SAHA and bortezomib for treating cancer
AU2006318652A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the HDAC inhibitor FK228
US20100137239A1 (en) * 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
CA2667348A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
AU2007342028B2 (en) * 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
US20100093610A1 (en) * 2006-12-29 2010-04-15 Vrolijk Nicholas H Romidepsin-based treatments for cancer
CA2676387A1 (en) * 2007-01-23 2008-07-31 Gloucester Pharmaceuticals, Inc. Combination therapy
RU2607634C2 (ru) 2010-07-12 2017-01-10 Селджин Корпорейшн Твердые формы ромидепсина и их применение
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
JP6170946B2 (ja) * 2012-01-12 2017-07-26 セルジーン コーポレイション ロミデプシン製剤及びその使用
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
US9410943B2 (en) 2013-03-14 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
EA037667B1 (ru) * 2013-08-22 2021-04-28 Ванда Фармасьютикалз Инк. Лечение рака
US20160228447A1 (en) * 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
AU2015284526B2 (en) * 2014-07-03 2018-05-17 Imclone Llc Combination therapy
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
EP3746135A4 (en) 2018-01-30 2022-03-09 Foghorn Therapeutics Inc. METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
US20230066136A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2023512040A (ja) 2020-01-29 2023-03-23 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60149520A (ja) * 1984-01-13 1985-08-07 Ajinomoto Co Inc 抗腫瘍剤
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US5696273A (en) * 1991-02-28 1997-12-09 Parfums Christian Dior Method for synthesizing cucurbitine
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
DE4137540A1 (de) * 1991-11-14 1993-05-19 Steigerwald Arzneimittelwerk Verwendung von praeparaten der curcuma-pflanzen
DE69333202T2 (de) * 1992-06-26 2004-03-18 The Trustees Of Princeton University Verfahren zur erkennung von krebszellen oder ihren vorstadien mittels p90 und p53-antikörper oder p90 und p53-sonden
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
IN188720B (pl) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
AU2903300A (en) * 1999-03-03 2000-09-21 Ida Royalty Aps Novel pharmaceuticals, dietary supplements and cosmetic compositions, and the use of certain mixtures for preparing medicament or a dietary supplement for thetreatment or prevention of inflammation, hypersensitivity reactions or pain
WO2001042282A1 (en) * 1999-12-08 2001-06-14 Xcyte Therapies, Inc. Depsipeptide and congeners thereof for use as immunosuppressants
US7056884B2 (en) * 2000-07-17 2006-06-06 Astellas Pharma Inc. Reduced FK228 and use thereof
US6613534B2 (en) * 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP4238728B2 (ja) * 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
CA2433479A1 (en) * 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
US8299126B2 (en) * 2003-02-27 2012-10-30 Leonard A. Cohen Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors

Also Published As

Publication number Publication date
DE602004027244D1 (de) 2010-07-01
MXPA06000013A (es) 2006-03-21
WO2005000332A3 (en) 2005-03-24
CY1113534T1 (el) 2016-06-22
DK2238982T3 (da) 2013-01-28
EP2238982B8 (en) 2013-01-16
EP2238982A3 (en) 2011-03-02
US20060223747A1 (en) 2006-10-05
PT2238982E (pt) 2013-01-22
US7056883B2 (en) 2006-06-06
EP2238982A2 (en) 2010-10-13
ES2341771T3 (es) 2010-06-28
EP2238982B1 (en) 2012-10-17
ES2397079T3 (es) 2013-03-04
CA2529840A1 (en) 2005-01-06
SI2238982T1 (sl) 2013-01-31
EP1638541B1 (en) 2010-05-19
US20050107290A1 (en) 2005-05-19
JP2007521259A (ja) 2007-08-02
EP1638541A2 (en) 2006-03-29
JP4661782B2 (ja) 2011-03-30
ATE468113T1 (de) 2010-06-15
WO2005000332A2 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
EP2238982B8 (en) Therapeutic agent for soft tissue sarcoma
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
WO2005063745A8 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
DE60329001D1 (en) 8-hydroxychinolinderivate
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
MX2007013624A (es) Inhibidores de proteina cinasa.
WO2008020027A3 (en) 2,5-dihydroxybenzene compounds for the treatment of skin cancer
HK1091121A1 (en) Substituted 2-aminotetralins for the treatment of depressions
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
TW200728307A (en) Novel spirochromanone derivatives
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
GEP20105134B (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
TW200639159A (en) Treatment of pain
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
EP2481429A3 (en) MMP Activated Vascular Disrupting Agents
WO2007047893A3 (en) Use of dasatinib for the treatment of bone metastasis
WO2006076569A3 (en) Bicyclic heterocycles as cannabinoid receptor modulators
TW200621794A (en) Pulmonary administration of an antithrombotic compound
UA90807C2 (ru) Производные триазолопиразина полезные как противораковые агенты